Suzhou Alphamab
China antibody-engineering biotech (mAbs, fusion proteins, bispecifics) -- private parent entity distinct from the HKEX-listed spinout Alphamab Oncology (9966.HK)
Privately held: no public share price · China
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-L1Monoclonal antibody | HIVNon-Small Cell Lung CancerChronic Hepatitis BEndometrial Cancer | |
| Phase 1/2 | Factor XI/XIa (FXI/FXIa)Monoclonal antibody | HypertensionChronic Kidney Disease |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
EnvafolimabPhase 1/2Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
Est. primary completion 2026-12 · NCT05024214 · CT.gov ↗
What to watch
Est. primary completion 2026-12 · NCT05112991 · CT.gov ↗
What to watch
2027 (3)
2029 (1)
June 2029 (1)
Est. primary completion 2029-06 · NCT04910386 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.